To further explore the molecular mechanism that leads to TGF-β release from IPF-derived PBMCs, we treated the cells with the two drugs that are actually used in therapy, nintedanib (10 nM), a tyrosine kinase inhibitor, and pirfenidone (0.1 μg/ml). Here, TGFB1 is linked to idiopathic pulmonary fibrosis.